FDA approves SUTENT for treatment of pancreatic NET

[News]

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.

More... (http://www.news-medical.net/news/20110521/FDA-approves-SUTENT-for-treatment-of-pancreatic-NET.aspx)